Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.59 |
| ▸ | AKR1C2 | P52895 | 7/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.59 |
| ▸ | CDC42 | P60953 | 1/20 | 0.59 |
| ▸ | RAC1 | P63000 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.59 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL506523 | 0.90 | TDP1 (0.71) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL31619540 | 0.90 | TDP1 (0.71) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL3280876 | 0.90 | TDP1 (0.71) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL10594020 | 0.85 | TDP1 (0.67) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL1122142 | 0.84 | TDP1 (0.74) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL10406806 | 0.84 | TDP1 (0.74) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL9284416 | 0.83 | TDP1 (1.00) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL10407187 | 0.82 | TDP1 (0.71) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL9717784 | 0.81 | TDP1 (0.78) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL8194894 | 0.81 | TDP1 (0.78) | TDP1L3MBTL1TSHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304409-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2012-11-06 | — | — | US | disclosed |
| US-8222277-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2012-07-17 | — | — | US | disclosed |
| US-8088762-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NICOX S.A. (FR) | 2012-01-03 | — | — | US | disclosed |
| US-20110098253-A1 | Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use | NICOX S.A. (IT) | 2011-04-28 | — | — | US | disclosed |
| US-7883714-B2 | (2R)-2,3-bis(nitrooxy)propyl(2S)-2(6-methoxy(2-naphthyl)propanoate, used for treating inflammation, pain and fever; gastrointestinal disorders; wound healing agents; preventing gastrointestinal, renal and/or respiratory toxicities; side effect reduction; kits | NICOX S.A. (FR) | 2011-02-08 | — | — | US | disclosed |
| US-20100137291-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NICOX SA (FR) | 2010-06-03 | — | — | US | disclosed |
| US-20100093671-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NICOX SA (FR) | 2010-04-15 | — | — | US | disclosed |
| US-20100093708-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NICOX SA (FR) | 2010-04-15 | — | — | US | disclosed |
| US-7163958-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED INC. (US) | 2007-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093708-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS1, NOS3 | TDP1 886/4885L3MBTL1 4657/4885TSHR 3425/4885 |
| US-20110098253-A1 | Nitrosated Nonsteroidal Antiinflammatory Compounds, Compositions and Methods of Use | NOS2, NOS1, NOS3 | TDP1 1034/4885L3MBTL1 4410/4885TSHR 3447/4885 |
| US-20100093671-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS1, NOS3 | TDP1 886/4885L3MBTL1 4657/4885TSHR 3425/4885 |
| US-20100137291-A1 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS1, NOS3 | TDP1 886/4885L3MBTL1 4657/4885TSHR 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.